Sagimet Biosciences SGMT 深 滬
已收盤 10-10 16:00:00 美东时间
7.675
-0.945
-10.96%
華盛通- 最 高8.675
- 今 開8.62
- 成交量 102.01万股
- 最 低 7.665
- 昨 收 8.62
- 總市值 2.47亿
- 52周最高 11.41
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.73
- 委 比 -9.09%
- 總股本 3219.53万
- 歷史最高 20.71
- 量 比 1.67
- 振 幅 11.72%
- 歷史最低 1.73
- 每 手 1
- 風險率 2.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Viking Therapeutics (NASDAQ:VKTX) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t...
10-09 23:33
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
Sagimet Biosciences announced that analyses of the Phase 2b FASCINATE-2 study showing denifanstat's effectiveness in improving fibrosis in advanced fibrosis patients will be presented at the AASLD Liver Meeting 2025. Results demonstrate significant fibrosis improvement and biomarker benefits in patients, particularly those with advanced baseline fibrosis. Denifanstat, a fatty acid synthase inhibitor, is under development for metabolic dysfunction...
10-07 11:00
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Maintains $28 Price Target
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $28 price target.
10-02 20:25
Sagimet Doses First Participants In Phase 1 Pharmacokinetic Trial Of Combination Of Oral Once-Daily FASN Inhibitor, Denifanstat, And THR-β Agonist, Resmetirom; Topline Data Expected In H1 2026
Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first
10-01 19:17
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
Sagimet Biosciences has initiated a Phase 1 trial combining denifanstat, a FASN inhibitor, with resmetirom, a THR-β agonist, targeting metabolic dysfunction-associated steatohepatitis (MASH). The trial aims to evaluate safety, tolerability, pharmacokinetics, and potential drug interactions. Topline data are expected in the first half of 2026, with plans to advance to Phase 2 if successful. The combination's synergistic effects were previously obs...
10-01 11:00
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
<p>Sagimet Biosciences Inc. will participate in a panel discussion at Fierce Biotech Week in Boston, October 7-9, 2025. Marie O’Farrell, Ph.D., Senior Vice President of Research and Development at Sagimet, will present on "How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROI" on Thursday, October 9, 2025, at 11:15am ET. The panel will focus on the use of AI in drug development, particularly Sa...
09-24 11:00
Roche deal to buy 89bio boosts MASH space
Shares of companies focused on developing drugs for a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Thursday after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) a...
09-18 22:41
歌礼制药-B(01672.HK)正与国家药监局进行地尼法司他的上市申请前沟通
【财华社讯】歌礼制药-B(01672.HK)公布，在2025年9月17日于法国巴黎举行的2025年欧洲皮肤病与性病学会(EADV)年会最新突破性研究专场上口头报...
09-18 09:38
Sagimet Confirms Phase 3 Denifanstat Success In Moderate To Severe Acne With EADV 2025 Oral Presentation In Paris Scheduled
Denifanstat met all primary and secondary endpoints versus placeboDenifanstat was generally well toleratedSagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in
09-17 19:16
